Welcome to LookChem.com Sign In|Join Free

CAS

  • or

54828-06-7

Post Buying Request

54828-06-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

54828-06-7 Usage

General Description

1,2-Dimethyl-4-nitro-1H-imidazole-5-carboxylic acid is a chemical compound with a molecular formula C7H7N3O4. It is a derivative of imidazole and is commonly used in the synthesis of pharmaceuticals and agrochemicals. 1,2-DIMETHYL-4-NITRO-1H-IMIDAZOLE-5-CARBOXYLIC ACID is known for its antimicrobial and antifungal properties, making it a valuable ingredient in the production of medicines and agricultural products. Additionally, it has been studied for its potential as an anti-cancer agent. 1,2-Dimethyl-4-nitro-1H-imidazole-5-carboxylic acid is an important chemical in various industries and research fields due to its unique chemical properties and potential applications.

Check Digit Verification of cas no

The CAS Registry Mumber 54828-06-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,8,2 and 8 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 54828-06:
(7*5)+(6*4)+(5*8)+(4*2)+(3*8)+(2*0)+(1*6)=137
137 % 10 = 7
So 54828-06-7 is a valid CAS Registry Number.

54828-06-7Relevant articles and documents

ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2

Kiselyov, Alexander S.,Piatnitski, Evgueni L.,Samet, Alexander V.,Kisliy, Victor P.,Semenov, Victor V.

, p. 1369 - 1375 (2007/10/03)

We have developed a series of novel potent ortho-substituted azole derivatives active against kinases VEGFR-1 and VEGFR-2. Both specific and dual ATP-competitive inhibitors of VEGFR-2 were identified. Kinase activity and selectivity could be controlled by varying the arylamido substituents at the azole ring. The most specific molecule (17) displayed >10-fold selectivity for VEGFR-2 over VEGFR-1. Compound activities in enzymatic and cell-based assays were in the range of activities for reported clinical and development candidates (IC50 30 × 10-5 cm/min) is indicative of their potential for intestinal absorption upon oral administration.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 54828-06-7